Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399046 | 1.00 | CES2 (0.43) | CES2CES1BCHEENPP2HPGD | |
| Hydrochloric Acid SCHEMBL29017070 | 0.98 | CES2 (0.41) | CES2CES1BCHEENPP2HPGD | |
| SCHEMBL25745449 | 0.87 | ENPP2 (0.42) | ENPP2ACHE | |
| SCHEMBL1074082 | 0.85 | CES2 (0.43) | CES2CES1BCHEHPGDERN1 | |
| SCHEMBL7203384 | 0.82 | LIPG (0.41) | CES2CES1BCHE | |
| SCHEMBL8611022 | 0.79 | CES2 (0.39) | CES2CES1BCHEENPP2HPGD | |
| SCHEMBL1359168 | 0.79 | CES2 (0.41) | CES2CES1BCHEHPGDERN1 | |
| SCHEMBL30464898 | 0.79 | CES2 (0.41) | CES2CES1BCHEHPGDERN1 | |
| SCHEMBL31282464 | 0.79 | CES2 (0.41) | CES2CES1BCHEHPGDERN1 | |
| SCHEMBL29468967 | 0.79 | ENPP2 (0.46) | CES2CES1ENPP2ACHENFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-117924295-A | Furimazine derivative and preparation method and application thereof | 广州博鹭腾生物科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| CN-114230552-B | Trifluoromethoxy dibenzothiophene, preparation method thereof and preparation method of related intermediate | 江苏广域化学有限公司 | 2023-11-03 | — | — | CN | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-1923385-B1 | Iridium complex, carbazole derivatives and copolymer having the same | KWANGJU INST SCI & TECH (KR) | 2009-05-27 | — | — | EP | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| US-20080177084-A1 | IRIDIUM COMPLEX, CARBAZOLE DERIVATIVES AND COPOLYMER HAVING THE SAME | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-07-24 | — | — | US | claimed |
| EP-1923385-A1 | Iridium complex, carbazole derivatives and copolymer having the same | Gwangju Institute of Science and Technology (KR) | 2008-05-21 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2006101779-A2 | NON-AQUEOUS ELECTROLYTES FOR LITHIUM ION BATTERIES | THE UNIVERSITY OF CHICAGO (US) | 2006-09-28 | — | — | WO | claimed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | CES2 18/4885CES1 9/4885BCHE 15/4885 |
| US-20080177084-A1 | IRIDIUM COMPLEX, CARBAZOLE DERIVATIVES AND COPOLYMER HAVING THE SAME | INTS9, HIRIP3, HELZ | CES2 3949/4885CES1 4170/4885BCHE 4204/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CES2 1317/4885CES1 1971/4885BCHE 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.